molecular-glue-1920x640
Webinar

Development of an assay and screening platform to study molecular glue degraders

Discover how targeting RNA-binding motif protein 39 (RBM39) is unlocking new possibilities in cancer treatment. Learn from experts at Abbvie and Fraunhofer ITMP in the use of molecular glue degraders and advanced HTRF technology to quantify RBM39 degradation in neuroblastoma cancer cells.

For research use only. Not for use in diagnostic procedures.

To view the full content please answer a few questions

By submitting my personal data, I acknowledge that Revvity Inc. and its affiliates (“Company”) will process my personal data provided above consistent with the Company’s Privacy Policy available here.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
molecular-glue-degraders